LTBR and pancreatic neuroendocrine tumor: Vessel normalization in combination with a vascular targeting peptide coupled to LIGHT, a ligand for the lymphotoxin β receptor, induced HEVs and tertiary lymphoid structures in Rip1-Tag5 pancreatic neuroendocrine tumors.